Effect of metabolic syndrome on mitsugumin 53 expression and function

PLoS ONE

Volumn 10, Issue 5, 2015, Pages

  Ma, Hanley ^a,b   Liu, Jason ^a,c   Bian, Zehua ^a   Cui, Yuqi ^a   Zhou, Xinyu ^a   Zhou, Xuefeng ^a   Zhang, Bo ^a,d   Adesanya, T M Ayodele ^a   Yi, Frank ^a   Park, Ki Ho ^a   Tan, Tao ^a   Chen, Zhishui ^d   Zhu, Hua ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Olentangy Liberty High School   (United States)

^c Dublin Jerome High School   (United States)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GLUCOSE; LOW DENSITY LIPOPROTEIN; MEMBRANE PROTEIN; MITSUGUMIN 53; UNCLASSIFIED DRUG; CARRIER PROTEIN; MG53 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY MASS; CELL PROTECTION; CELLULAR DISTRIBUTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HEART MUSCLE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; LIPID DIET; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; MOUSE; MUSCLE MITOCHONDRION; NONHUMAN; OXIDATIVE STRESS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SKELETAL MUSCLE; TISSUE REPAIR; WESTERN BLOTTING; WILD TYPE MOUSE; ADVERSE EFFECTS; ANIMAL; BLOOD; CARDIAC MUSCLE; CHEMICALLY INDUCED; DISEASE MODEL; DOWN REGULATION; METABOLISM; MITOCHONDRION;

MUS;

ANIMALS; CARRIER PROTEINS; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DOWN-REGULATION; METABOLIC SYNDROME X; MICE; MITOCHONDRIA; MUSCLE, SKELETAL; MYOCARDIUM; OXIDATIVE STRESS;

EID: 84929082601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0124128     Document Type: Article

References (26)

1. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, et al. The metabolic syndrome. Endocrine reviews. 2008; 29(7):777-822. doi: 10.1210/er.2008-0024 PMID: 18971485
2. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes care. 2001; 24(4):683-9. PMID: 11315831
3. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW, et al. Obesity and the metabolic syndrome in children and adolescents. The New England journal of medicine. 2004; 350(23):2362-74. PMID: 15175438
4. Moller DE, Kaufman KD. Metabolic syndrome: a clinical and molecular perspective. Annual review of medicine. 2005; 56:45-62. PMID: 15660501
5. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circulation research. 2010; 107(9):1058-70. doi: 10.1161/CIRCRESAHA.110.223545 PMID: 21030723
6. Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiological reviews. 2013; 93(1):137-88. doi: 10.1152/physrev.00045.2011 PMID: 23303908
7. Cai C, Masumiya H, Weisleder N, Matsuda N, Nishi M, Hwang M, et al. MG53 nucleates assembly of cell membrane repair machinery. Nat Cell Biol. 2009; 11(1):56-64. doi: 10.1038/ncb1812 PMID: 19043407
8. Wang X, Xie W, Zhang Y, Lin P, Han L, Han P, et al. Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res. 2010; 107(1):76-83. doi: 10.1161/CIRCRESAHA.109.215822 PMID: 20466981
9. Weisleder N, Takizawa N, Lin P, Wang X, Cao C, Zhang Y, et al. Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy. Sci Transl Med. 2012; 4(139):139ra85. doi: 10.1126/scitranslmed.3003921 PMID: 22723464
10. He B, Tang RH, Weisleder N, Xiao B, Yuan Z, Cai C, et al. Enhancing muscle membrane repair by gene delivery of MG53 ameliorates muscular dystrophy and heart failure in delta-Sarcoglycan-deficient hamsters. Mol Ther. 2012; 20(4):727-35. doi: 10.1038/mt.2012.5 PMID: 22314291
11. Zhu H, Lin P, De G, Choi KH, Takeshima H, Weisleder N, et al. Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair. J Biol Chem. 2011; 286(15):12820-4. doi: 10.1074/jbc.C111.221440 PMID: 21343302
12. Jia Y, Chen K, Lin P, Lieber G, Nishi M, Yan R, et al. Treatment of acute lung injury by targeting MG53-mediated cell membrane repair. Nature communications. 2014; 5:4387. Epub 2014/07/19. doi: 10.1038/ncomms5387 PMID: 25034454
13. Zhang Y, Lv F, Jin L, Peng W, Song R, Ma J, et al. MG53 participates in ischaemic postconditioning through the RISK signalling pathway. Cardiovascular research. 2011; 91(1):108-15. doi: 10.1093/cvr/cvr029 PMID: 21285295
14. Cao CM, Zhang Y, Weisleder N, Ferrante C, Wang X, Lv F, et al. MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation. 2010; 121(23):2565-74. doi: 10.1161/CIRCULATIONAHA.110.954628 PMID: 20516375
15. Yi JS, Park JS, Ham YM, Nguyen N, Lee NR, Hong J, et al. MG53-induced IRS-1 ubiquitination negatively regulates skeletal myogenesis and insulin signalling. Nature communications. 2013; 4:2354. doi: 10.1038/ncomms3354 PMID: 23965929
16. Song R, Peng W, Zhang Y, Lv F, Wu HK, Guo J, et al. Central role of E3 ubiquitin ligase MG53 in insulin resistance and metabolic disorders. Nature. 2013; 494(7437):375-9. doi: 10.1038/nature11834 PMID: 23354051
17. Yuan H, Niu Y, Liu X, Yang F, Niu W, Fu L. Proteomic analysis of skeletal muscle in insulin-resistant mice: response to 6-week aerobic exercise. PloS one. 2013; 8(1):e53887. doi: 10.1371/journal.pone.0053887 PMID: 23326526
18. Xu Y, Ma LL, Zhou C, Zhang FJ, Kong FJ, Wang WN, et al. Hypercholesterolemic myocardium is vulnerable to ischemia-reperfusion injury and refractory to sevoflurane-induced protection. PloS one. 2013; 8(10):e76652. doi: 10.1371/journal.pone.0076652 PMID: 24124583
19. Ma LL, Zhang FJ, Qian LB, Kong FJ, Sun JF, Zhou C, et al. Hypercholesterolemia blocked sevoflurane-induced cardioprotection against ischemia-reperfusion injury by alteration of the MG53/RISK/GSK3beta signaling. International journal of cardiology. 2013; 168(4):3671-8. doi: 10.1016/j.ijcard.2013.06.037 PMID: 23856444
20. Terauchi Y, Iwamoto K, Tamemoto H, Komeda K, Ishii C, Kanazawa Y, et al. Development of non-insulin-dependent diabetes mellitus in the double knockout mice with disruption of insulin receptor sub-strate-1 and beta cell glucokinase genes. Genetic reconstitution of diabetes as a polygenic disease. The Journal of clinical investigation. 1997; 99(5):861-6. PMID: 9062343
21. Tamemoto H, Kadowaki T, Tobe K, Yagi T, Sakura H, Hayakawa T, et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature. 1994; 372(6502):182-6. PMID: 7969452
22. Laustsen PG, Michael MD, Crute BE, Cohen SE, Ueki K, Kulkarni RN, et al. Lipoatrophic diabetes in Irs1(-/-)/Irs3(-/-) double knockout mice. Genes & development. 2002; 16(24):3213-22.
23. Withers DJ, Gutierrez JS, Towery H, Burks DJ, Ren JM, Previs S, et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature. 1998; 391(6670):900-4. PMID: 9495343
24. Kubota N, Tobe K, Terauchi Y, Eto K, Yamauchi T, Suzuki R, et al. Disruption of insulin receptor substrate 2 causes type 2 diabetes because of liver insulin resistance and lack of compensatory beta-cell hyperplasia. Diabetes. 2000; 49(11):1880-9. PMID: 11078455
25. Long YC, Cheng Z, Copps KD, White MF. Insulin receptor substrates Irs1 and Irs2 coordinate skeletal muscle growth and metabolism via the Akt and AMPK pathways. Molecular and cellular biology. 2011; 31(3):430-41. doi: 10.1128/MCB.00983-10 PMID: 21135130
26. Howard AC, McNeil AK, Xiong F, Xiong WC, McNeil PL. A novel cellular defect in diabetes: membrane repair failure. Diabetes. 2011; 60(11):3034-43. doi: 10.2337/db11-0851 PMID: 21940783